BPC-157 + TB-500: dosing evidence
> Updated:
Calculate the BPC-157 + TB-500 Blend dose
Enter your dose and diluent volume for BPC-157 + TB-500 Blend — the calculator will do the rest.
Human dosing
| Period / condition | Dose | Escalation |
|---|---|---|
| Loading phase (weeks 1-4) | BPC-157 250-500 mcg/day SubQ + TB-500 2-2.5 mg twice weekly | Starting dose |
| Maintenance phase (weeks 5-8) | BPC-157 250 mcg/day + TB-500 2 mg weekly | Maximum in this schedule |
| Course length | 4-8 weeks (up to 12 for chronic cases) | , |
Background on the molecule, its mechanism and primary sources is covered in the monograph.
Practical dosage and effect notes
No controlled clinical data exist on dosing this specific combination, and the schedule on this page is drawn from public research protocols. Splitting it into a loading phase (weeks 1–4) and a maintenance phase (weeks 5–8) is common logic in those protocols: a higher starting dose is stepped down once a cumulative effect, as reported by users of the protocol, is established.
The two peptides' different frequency in the table (BPC-157 daily, TB-500 once or twice weekly) reflects the difference in administration model this page describes: BPC-157 is more often placed nearer the area of interest and injected more frequently, while TB-500 acts systemically from any site, so published protocols less often call for daily dosing to sustain a systemic effect.
This is background for planning a research protocol, not a medical recommendation and not instructions for self-administration.
How to reconstitute
An example reconstitution for convenient dosing. The exact ratios depend on your vial. For research reference only — not medical guidance.
- 1Add the diluentUse bacteriostatic water. Example: 2 ml into a 20 mg vial.BPC-157 + TB-500 Blend20 mg+ 2 mlDiluent
- 2Get the concentrationExample: 20 mg in 2 ml =BPC-157 + TB-500 Blend10 mg/ml(10,000 mcg/ml)
- 3Work out the volume per doseFor example, for a 5 mg dose:5 mg = 0.5 ml= 50 u. (U-100)
This is only an example calculation. You can use a different diluent volume — plug your own numbers into the calculator. Open calculator →
Research protocols
BPC-157 + TB-500 Blend: reference regimens
Controlled data on this compound are limited.
Both peptides are typically given subcutaneously (SubQ); BPC-157 is often placed nearer the area of interest, while TB-500 acts systemically from any site.
TB-500 (a synthetic Thymosin Beta-4 fragment) gets searched on its own more often than the BPC-157 combination, so this section covers TB-500 dosing within this blend specifically, not a general overview of the peptide.
More scientific background in the BPC-157 + TB-500 Blend monograph
Notes and safety
- • BPC-157 + TB-500 Blend is a research peptide. Human safety and efficacy data are limited.
- • The regimens shown are based on publications and research protocols, not clinical recommendations.
- • Individual reactions may vary. Published protocols typically start dosing at the lower end of the reported range.
- • Not recommended for use with chronic illness, pregnancy, or breastfeeding.
- • This information is for educational purposes and is not medical advice.
BPC-157 + TB-500 Blend